Trial Profile
An Observational Post-authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (XARELTO) Initiated in Secondary Care for the Prevention of Atherothrombotic Events in Patients Who Have Had Acute Coronary Syndrome in England and Wales
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Atherosclerosis
- Focus Adverse reactions
- Sponsors Bayer
- 28 Jan 2016 Accrual to date is 8% according to United Kingdom Clinical Research Network record.
- 28 Jan 2016 Planned End Date changed from 1 Sep 2018 to 1 Jun 2019 according to United Kingdom Clinical Research Network record.
- 10 Nov 2015 Accrual to date is 2% according to United Kingdom Clinical Research Network record.